Author

Julian Panés

UEG Week+ | Clinical trials in IBD: Endpoint missed?
UEG Week+ | Clinical trials in IBD: Endpoint missed?

Julian Panés  et al.

THERAPEUTIC DRUG MONITORING DOSING REGIMEN WITH ADALIMUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE SERENE-UC MAINTENANCE STUDY
THERAPEUTIC DRUG MONITORING DOSING REGIMEN WITH ADALIMUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE SERENE-UC MAINTENANCE STUDY

Julian Panés  et al.

ETROLIZUMAB AS INDUCTION AND MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: RESULTS FROM THE PHASE 3 BERGAMOT STUDY
ETROLIZUMAB AS INDUCTION AND MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: RESULTS FROM THE PHASE 3 BERGAMOT STUDY

Julian Panés  et al.

TOFACITINIB FOR THE TREATMENT OF ULCERATIVE COLITIS: UP TO 6.8 YEARS OF SAFETY DATA FROM GLOBAL CLINICAL TRIALS
TOFACITINIB FOR THE TREATMENT OF ULCERATIVE COLITIS: UP TO 6.8 YEARS OF SAFETY DATA FROM GLOBAL CLINICAL TRIALS

Julian Panés  et al.

COMPOSITE AND INDIVIDUAL MEASURES OF EFFICACY AND SAFETY AFTER 2 YEARS OF UPADACITINIB TREATMENT FOR CROHN'S DISEASE: RESULTS FROM THE ONGOING PHASE 2 CELEST OPEN-LABEL EXTENSION STUDY
COMPOSITE AND INDIVIDUAL MEASURES OF EFFICACY AND SAFETY AFTER 2 YEARS OF UPADACITINIB TREATMENT FOR CROHN'S DISEASE: RESULTS FROM THE ONGOING PHASE 2 CELEST OPEN-LABEL EXTENSION STUDY

Julian Panés  et al.

SWITCH FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB THERAPY IN CLINICAL PRACTICE: EFFICACY AND SAFETY IN INFLAMMATORY BOWEL DISEASE
SWITCH FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB THERAPY IN CLINICAL PRACTICE: EFFICACY AND SAFETY IN INFLAMMATORY BOWEL DISEASE

Julian Panés  et al.

UPADACITINIB 30 MG TREATMENT RESTORES CLINICAL RESPONSE AFTER LOSS OF RESPONSE IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: RESULTS FROM THE PHASE 3 U-ENDURE STUDY
UPADACITINIB 30 MG TREATMENT RESTORES CLINICAL RESPONSE AFTER LOSS OF RESPONSE IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: RESULTS FROM THE PHASE 3 U-ENDURE STUDY

Julian Panés  et al.

AN UPDATE ON THE ANALYSIS OF NON-MELANOMA SKIN CANCER IN THE TOFACITINIB ULCERATIVE COLITIS CLINICAL PROGRAMME AS OF MAY 2019
AN UPDATE ON THE ANALYSIS OF NON-MELANOMA SKIN CANCER IN THE TOFACITINIB ULCERATIVE COLITIS CLINICAL PROGRAMME AS OF MAY 2019

Julian Panés  et al.

52-WEEKS RISANKIZUMAB SUBCUTANEOUS MAINTENANCE DOSING IS EFFICACIOUS AND WELL TOLERATED IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE WHO HAD DELAYED RESPONSE TO 12-WEEKS IV RISANKIZUMAB INDUCTION
52-WEEKS RISANKIZUMAB SUBCUTANEOUS MAINTENANCE DOSING IS EFFICACIOUS AND WELL TOLERATED IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE WHO HAD DELAYED RESPONSE TO 12-WEEKS IV RISANKIZUMAB INDUCTION

Julian Panés  et al.

AN ADDITIONAL 12 WEEKS OF RISANKIZUMAB THERAPY INDUCES CLINICAL RESPONSE IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE WHO FAILED TO ACHIEVE CLINICAL RESPONSE AFTER AN INITIAL INDUCTION PERIOD: 24-WEEK POOLED ANALYSIS OF TWO PHASE 3 STUDIES
AN ADDITIONAL 12 WEEKS OF RISANKIZUMAB THERAPY INDUCES CLINICAL RESPONSE IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE WHO FAILED TO ACHIEVE CLINICAL RESPONSE AFTER AN INITIAL INDUCTION PERIOD: 24-WEEK POOLED ANALYSIS OF TWO PHASE 3 STUDIES

Julian Panés  et al.

EARLY AND DURABLE SYMPTOM CONTROL IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH ETRASIMOD (APD334) IN THE RANDOMISED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 2 OASIS TRIAL AND OPEN LABEL EXTENSION
EARLY AND DURABLE SYMPTOM CONTROL IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH ETRASIMOD (APD334) IN THE RANDOMISED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 2 OASIS TRIAL AND OPEN LABEL EXTENSION

Julian Panés  et al.

ETRASIMOD IMPROVES QUALITY OF LIFE IN ADULTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2 OASIS TRIAL AND OPEN-LABEL EXTENSION
ETRASIMOD IMPROVES QUALITY OF LIFE IN ADULTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2 OASIS TRIAL AND OPEN-LABEL EXTENSION

Julian Panés  et al.

EFFICACY AND SAFETY OF ETRASIMOD IN PATIENTS WITH MODERATE TO SEVERE ISOLATED PROCTITIS RELATIVE TO THOSE WITH MORE EXTENSIVE COLITIS: RESULTS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS
EFFICACY AND SAFETY OF ETRASIMOD IN PATIENTS WITH MODERATE TO SEVERE ISOLATED PROCTITIS RELATIVE TO THOSE WITH MORE EXTENSIVE COLITIS: RESULTS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS

Julian Panés  et al.

HEALTH-RELATED QUALITY OF LIFE FROM THE INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE AMONG PATIENTS WITH ULCERATIVE COLITIS STRATIFIED BY PRIOR AND CONCOMITANT THERAPIES: RESULTS FROM THE ETRASIMOD ELEVATE UC CLINICAL PROGRAMME
HEALTH-RELATED QUALITY OF LIFE FROM THE INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE AMONG PATIENTS WITH ULCERATIVE COLITIS STRATIFIED BY PRIOR AND CONCOMITANT THERAPIES: RESULTS FROM THE ETRASIMOD ELEVATE UC CLINICAL PROGRAMME

Julian Panés  et al.

TREAT-TO-TARGET MAINTENANCE EFFICACY AND PHARMACOKINETICS OF USTEKINUMAB DOSING REGIMEN UP TO WEEK 48 IN THE STARDUST TRIAL
TREAT-TO-TARGET MAINTENANCE EFFICACY AND PHARMACOKINETICS OF USTEKINUMAB DOSING REGIMEN UP TO WEEK 48 IN THE STARDUST TRIAL

Julian Panés  et al.

USTEKINUMAB IMPROVES HEALTH-RELATED QUALITY-OF-LIFE IN PATIENTS WITH MODERATE-TO-SEVERE CROHN´S DISEASE: RESULTS FROM A WEEK 16 INTERIM ANALYSIS OF THE STARDUST TRIAL
USTEKINUMAB IMPROVES HEALTH-RELATED QUALITY-OF-LIFE IN PATIENTS WITH MODERATE-TO-SEVERE CROHN´S DISEASE: RESULTS FROM A WEEK 16 INTERIM ANALYSIS OF THE STARDUST TRIAL

Julian Panés  et al.

USTEKINUMAB IMPROVES HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH MODERATE-TO-SEVERE CROHN’S DISEASE: RESULTS UP TO WEEK 104 OF THE STARDUST TRIAL
USTEKINUMAB IMPROVES HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH MODERATE-TO-SEVERE CROHN’S DISEASE: RESULTS UP TO WEEK 104 OF THE STARDUST TRIAL

Julian Panés  et al.

HERPES ZOSTER INFECTION IN PATIENTS WITH ULCERATIVE COLITIS RECEIVING TOFACITINIB: RESULTS FROM THE PHASE 2 AND PHASE 3 CLINICAL PROGRAMMES
HERPES ZOSTER INFECTION IN PATIENTS WITH ULCERATIVE COLITIS RECEIVING TOFACITINIB: RESULTS FROM THE PHASE 2 AND PHASE 3 CLINICAL PROGRAMMES

Julian Panés  et al.

EFFICACY OF UPADACITINIB ON LUMINAL STENOSIS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: A POST HOC ANALYSIS OF PHASE 3 STUDIES
EFFICACY OF UPADACITINIB ON LUMINAL STENOSIS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: A POST HOC ANALYSIS OF PHASE 3 STUDIES

Julian Panés  et al.

MATCHING-ADJUSTED INDIRECT COMPARISONOF UPADACITINIB VERSUS VEDOLIZUMAB AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
MATCHING-ADJUSTED INDIRECT COMPARISONOF UPADACITINIB VERSUS VEDOLIZUMAB AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

Julian Panés  et al.

Item 21 - 40 / 71
1
2
3 4